Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ancient herbs meet modern viruses in fight against superbug pneumonia

NCT ID NCT07612605

Disease control Sponsor: Chinese PLA General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial will test a combination of a Chinese herbal formula (Yiqi Huoxue Jiedu) and bacteriophages (viruses that target bacteria) in 250 people with severe pneumonia caused by drug-resistant bacteria. The goal is to see if this combo can clear the infection faster and reduce deaths. The study is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Yiqi Huoxue Jiedu formula (herbal mix) and bacteriophages (viruses that kill bacteria)
What this could lead to
If it works, this could point toward a new way to treat severe pneumonia caused by drug-resistant bacteria, potentially lowering death rates.
What could go wrong
This is a very early (Phase 1) trial, so safety and effectiveness are not yet proven. The combination therapy may not work better than standard care, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who meet the diagnostic criteria for severe pneumonia caused by drug-resistant Gram-negative bacilli and conform to the TCM syndrome differentiation of Qi deficiency, toxin accumulation and blood stasis syndrome; * Patients confirmed by rapid on-site microbiological evaluation (M-ROSE), clinical microbial culture and drug susceptibility testing (based on the drug susceptibility test results of our hospital or other Grade A tertiary hospitals) to be infected with multidrug-resistant Klebsiella pneumoniae, Acinetobacter baumannii or Pseudomonas aeruginosa; * Aged 18 to 85 years old; * Patients or their family members agree to cooperate with the collection of upper and lower respiratory tract specimens, consent to bronchoscopy plus bronchoalveolar lavage, and agree to receive nebulized inhalation of bacteriophage therapy; * Patients or their family members have fully read, understood and signed the informed consent form. Exclusion Criteria: * Women who are pregnant or lactating; * Patients with immunodeficiency; * Patients receiving immunosuppressive therapy or suffering from immunodeficiency diseases; * Patients who have received mechanical ventilation for more than 60 days prior to enrollment; * Patients with active pulmonary tuberculosis, lung abscess, or Grade D chronic obstructive pulmonary disease (COPD); * Patients with incomplete sampling or clinical data; * Patients with known allergies to bacteriophage products or the components of Yiqi Huoxue Jiedu Formula; * Patients judged by the researchers as unsuitable for participation in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pneumonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pneumonia pneumonia caused by gram negative bacteria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pneumonia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • 1st Medical Center of Chinese PLA General Hospital

    Beijing, China

  • 8th Medical Center of Chinese PLA General Hospital

    Beijing, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangdong, Guangzhou, China

  • The First Affiliated Hospital of Guangzhou University of Chinese Medicine

    Guangdong, Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.